Histogenics and FDA Conclude Discussions Regarding NeoCart® Phase 3 ...
12/21/18
Histogenics and FDA Conclude Discussions Regarding NeoCart® Phase 3 Clinical Trial Data and Regulatory Pathway GlobeNewswire
Histogenics to Discontinue Development of NeoCart and Explore Strategic Alternatives ‒
[more]